Tyra Biosciences Inc
TYRA
NASDAQ
Biotechnology
$25.29
USD
+0.27 (+1.08%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $1.49B
Volume 420.4K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-148.56M
TTM
-40.4%
YoY
Operating Cash Flow
$-109.65M
TTM
-26.6%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 7.1 | 7.5 | 8.3 | 8.5 | 9.8 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 31.5 | 32.9 | 36.5 | 42.0 | 49.0 |
Operating Income | -31.5 | -32.9 | -36.5 | -42.0 | -49.0 |
EBITDA | -31.3 | -32.8 | -36.4 | -41.9 | -48.9 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 3.4 | 3.1 | 2.7 | 2.7 | 3.4 |
Income Before Income Taxes | -28.1 | -29.9 | -33.8 | -39.3 | -45.6 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -28.1 | -29.9 | -33.8 | -39.3 | -45.6 |
Consolidated Net Income / Loss | -28.1 | -29.9 | -33.8 | -39.3 | -45.6 |
Net Income Attributable to Common Shareholders | -28.1 | -29.9 | -33.5 | -39.3 | -45.6 |
Basic EPS | -$0.47 | -$0.50 | -$0.56 | -$0.64 | -$0.69 |
Diluted EPS | -$0.47 | -$0.50 | -$0.56 | -$0.64 | -$0.69 |
Basic Shares Outstanding | 59.6M | 59.7M | 59.9M | 61.7M | 66.0M |
Diluted Shares Outstanding | 59.6M | 59.7M | 59.9M | 61.7M | 66.0M |